China
· Delayed Price · Currency is CNY Sirio Pharma Statistics
Total Valuation
Sirio Pharma has a market cap or net worth of CNY 7.71 billion. The enterprise value is 8.70 billion.
| Market Cap | 7.71B |
| Enterprise Value | 8.70B |
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | May 27, 2025 |
Share Statistics
Sirio Pharma has 306.40 million shares outstanding. The number of shares has decreased by -0.65% in one year.
| Current Share Class | 306.40M |
| Shares Outstanding | 306.40M |
| Shares Change (YoY) | -0.65% |
| Shares Change (QoQ) | -0.77% |
| Owned by Insiders (%) | 20.71% |
| Owned by Institutions (%) | 20.84% |
| Float | 111.52M |
Valuation Ratios
The trailing PE ratio is 23.08 and the forward PE ratio is 19.65.
| PE Ratio | 23.08 |
| Forward PE | 19.65 |
| PS Ratio | 1.83 |
| PB Ratio | 2.84 |
| P/TBV Ratio | 4.66 |
| P/FCF Ratio | 24.95 |
| P/OCF Ratio | 10.97 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.82, with an EV/FCF ratio of 28.14.
| EV / Earnings | 26.31 |
| EV / Sales | 2.06 |
| EV / EBITDA | 13.82 |
| EV / EBIT | 20.66 |
| EV / FCF | 28.14 |
Financial Position
The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.57.
| Current Ratio | 2.26 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 2.47 |
| Debt / FCF | 5.03 |
| Interest Coverage | 4.14 |
Financial Efficiency
Return on equity (ROE) is 9.87% and return on invested capital (ROIC) is 5.99%.
| Return on Equity (ROE) | 9.87% |
| Return on Assets (ROA) | 4.90% |
| Return on Invested Capital (ROIC) | 5.99% |
| Return on Capital Employed (ROCE) | 8.88% |
| Revenue Per Employee | 1.52M |
| Profits Per Employee | 119,118 |
| Employee Count | 2,776 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 5.53 |
Taxes
In the past 12 months, Sirio Pharma has paid 27.56 million in taxes.
| Income Tax | 27.56M |
| Effective Tax Rate | 8.83% |
Stock Price Statistics
The stock price has increased by +18.79% in the last 52 weeks. The beta is 0.56, so Sirio Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +18.79% |
| 50-Day Moving Average | 21.66 |
| 200-Day Moving Average | 20.62 |
| Relative Strength Index (RSI) | 58.17 |
| Average Volume (20 Days) | 11,045,655 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sirio Pharma had revenue of CNY 4.21 billion and earned 330.67 million in profits. Earnings per share was 1.09.
| Revenue | 4.21B |
| Gross Profit | 1.34B |
| Operating Income | 420.96M |
| Pretax Income | 312.19M |
| Net Income | 330.67M |
| EBITDA | 594.31M |
| EBIT | 420.96M |
| Earnings Per Share (EPS) | 1.09 |
Balance Sheet
The company has 691.84 million in cash and 1.56 billion in debt, giving a net cash position of -863.42 million or -2.82 per share.
| Cash & Cash Equivalents | 691.84M |
| Total Debt | 1.56B |
| Net Cash | -863.42M |
| Net Cash Per Share | -2.82 |
| Equity (Book Value) | 2.71B |
| Book Value Per Share | 8.50 |
| Working Capital | 1.10B |
Cash Flow
In the last 12 months, operating cash flow was 702.80 million and capital expenditures -393.69 million, giving a free cash flow of 309.10 million.
| Operating Cash Flow | 702.80M |
| Capital Expenditures | -393.69M |
| Free Cash Flow | 309.10M |
| FCF Per Share | 1.01 |
Margins
Gross margin is 31.90%, with operating and profit margins of 9.99% and 7.85%.
| Gross Margin | 31.90% |
| Operating Margin | 9.99% |
| Pretax Margin | 7.41% |
| Profit Margin | 7.85% |
| EBITDA Margin | 14.10% |
| EBIT Margin | 9.99% |
| FCF Margin | 7.34% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 1.95%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 1.95% |
| Dividend Growth (YoY) | -23.18% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 66.72% |
| Buyback Yield | 0.65% |
| Shareholder Yield | 2.54% |
| Earnings Yield | 4.29% |
| FCF Yield | 4.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 27, 2025. It was a forward split with a ratio of 1.3.
| Last Split Date | May 27, 2025 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
Sirio Pharma has an Altman Z-Score of 2.95 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.95 |
| Piotroski F-Score | 6 |